IP Verse

Medimmune competitive analysis

Loading summary...

Latest patents of Medimmune opposed by its competitors

Explore Medimmune's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3218406
Oct 2, 2024Binding Molecules Specific For Cd73 And Uses Thereof2
EP3157629
Oct 5, 2022Methods Of Cancer Treatment With Antagonists Against Pd-1 And Pd-L1 In Combination With Radiation Therapy1
EP1942939
Jul 7, 2021Interleukin-13 Antibody Composition1
EP3329018
Mar 31, 2021Methods For Treating Hepcidin-Mediated Disorders1
EP2997036
Mar 3, 2021Purification Of Recombinantly Produced Polypeptides2
EP2935268
Feb 17, 2021Pyrrolobenzodiazepines And Conjugates Thereof1
EP2624859
Mar 1, 2017Factor Ii And Fibrinogen For Treatment Of Haemostatic Disorders1

Latest publications and patents of Medimmune New

Explore the latest publications and patents granted to Medimmune, showcasing their recent innovations and technological advancements.

Last updated on: Oct 20, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Medimmune

EP3218406
Oct 2, 2024Binding Molecules Specific For Cd73 And Uses ThereofPatent Maintained As Amended
EP3157629
Oct 5, 2022Methods Of Cancer Treatment With Antagonists Against Pd-1 And Pd-L1 In Combination With Radiation TherapyOpposition Rejected
EP1942939
Jul 7, 2021Interleukin-13 Antibody CompositionPatent Maintained As Amended
EP3329018
Mar 31, 2021Methods For Treating Hepcidin-Mediated DisordersRevoked
EP2997036
Mar 3, 2021Purification Of Recombinantly Produced PolypeptidesGranted And Under Opposition
EP2935268
Feb 17, 2021Pyrrolobenzodiazepines And Conjugates ThereofPatent Maintained As Amended
EP3072525
Jan 31, 2018Methods Of Reducing Basophil LevelsNo Opposition Filed Within Time Limit
EP2718320
Jan 10, 2018Anti-Pseudomonas Psl Binding Molecules And Uses ThereofNo Opposition Filed Within Time Limit
EP2624859
Mar 1, 2017Factor Ii And Fibrinogen For Treatment Of Haemostatic DisordersRevoked

Latest PTAB cases involving Medimmune

Discover the latest PTAB cases involving Medimmune, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Medimmune with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
MEDIMMUNE - 9 - -
GLAXOSMITHKLINE29112812
JAMES POOLE153 - - -
STRAWMAN336 - - -